Abstract
BackgroundPharmacovigilance and safety reporting, which involve processes for monitoring the use of medicines in clinical trials, play a critical role in the identification of previously unrecognized adverse events or changes in the patterns of adverse events.ObjectiveThis study aims to demonstrate the feasibility of automating the coding of adverse events described in the narrative section of the serious adverse event report forms to enable statistical analysis of the aforementioned patterns.MethodsWe used the Unified Medical Language System (UMLS) as the coding scheme, which integrates 217 source vocabularies, thus enabling coding against other relevant terminologies such as the International Classification of Diseases–10th Revision, Medical Dictionary for Regulatory Activities, and Systematized Nomenclature of Medicine). We used MetaMap, a highly configurable dictionary lookup software, to identify the mentions of the UMLS concepts. We trained a binary classifier using Bidirectional Encoder Representations from Transformers (BERT), a transformer-based language model that captures contextual relationships, to differentiate between mentions of the UMLS concepts that represented adverse events and those that did not.ResultsThe model achieved a high F1 score of 0.8080, despite the class imbalance. This is 10.15 percent points lower than human-like performance but also 17.45 percent points higher than that of the baseline approach.ConclusionsThese results confirmed that automated coding of adverse events described in the narrative section of serious adverse event reports is feasible. Once coded, adverse events can be statistically analyzed so that any correlations with the trialed medicines can be estimated in a timely fashion.
Highlights
Modern health care is associated with increased costs and broad-reaching variations in care and outcomes across the global population
These results confirmed that automated coding of adverse events described in the narrative section of serious adverse event reports is feasible
Our review of text mining applications related to the identification of adverse events revealed that this source of data was underrepresented. This study addresses this gap by using serious adverse event (SAE) report forms collected during clinical trials as the primary source of data
Summary
Background Modern health care is associated with increased costs and broad-reaching variations in care and outcomes across the global population. Pharmacovigilance and safety reporting are among the most important aspects of the conduct of clinical trials This is relevant to all clinical trials in which the benefit https://medinform.jmir.org/2021/12/e28632 XSLFO RenderX. Pharmacovigilance and safety reporting provide the basis for ensuring clinical trial participant safety and good research practice It involves processes for monitoring the use of medicines or interventions in clinical trials. It has a critical role in the identification of previously unrecognized adverse events or changes in the patterns of adverse events. Pharmacovigilance and safety reporting, which involve processes for monitoring the use of medicines in clinical trials, play a critical role in the identification of previously unrecognized adverse events or changes in the patterns of adverse events
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.